Drugs / COVID-19 Convalescent Plasma (CCP)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04421404 | Jun 2020 → Apr 2021 | COVID-19 | Priscilla Hsue, MD | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | COVID-19 Convalescent Plasma (CCP) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04421404 ↗ |
| Known as | CCP | “COVID-19 Convalescent Plasma (CCP) is a form of passive antibody therapy that involves the administration of anti-SARS-CoV-2 antibodies to a susceptible individual for the...” NCT04421404 ↗ |
| Modality | Protein / enzyme biologic | “a form of passive antibody therapy” NCT04421404 ↗ |
| Route | Other | “single infusion of 250 ml anti-SARS-CoV-2 convalescent fresh frozen plasma” NCT04421404 ↗ |